Henlius and Sandoz have expanded their oncology biosimilars partnership into a broader global collaboration covering up to 10 proposed monoclonal antibody and antibody-drug conjugate biosimilar assets or components. The Aug. 17, 2026 agreement includes collaboration terms for three initial products — HLX05-N, a proposed cetuximab biosimilar; HLX16, a proposed evolocumab biosimilar; and a proposed belimumab biosimilar — as well as an option for HLXTE-HAase1001, a recombinant human hyaluronidase. Henlius said Sandoz will receive exclusive rights for registration and commercialization outside China for up to 10 partnered products worldwide, while Henlius will lead development, manufacturing and supply. Based on the initial arrangements, Sandoz will pay Henlius an upfront payment, milestone payments and a non-refundable option fee totaling up to $322 million, and Henlius expects total invoiced amount in 2026 of up to $100.5 million. The companies said the new agreement builds on their April 2025 exclusive commercialization partnership for HLX13, Henlius's proposed ipilimumab biosimilar, across 46 countries and regions including Europe and the United States. Most of the newly partnered assets are at early stages of development, with HLX05-N having dosed its first patient in a Phase 1 study in China in July 2026, while HLX16 and the proposed belimumab biosimilar are in preclinical research and HLXTE-HAase1001 is in process development. Henlius cited IQVIA MIDAS data showing 2025 global sales of about $1.696 billion for cetuximab, $6.602 billion for evolocumab and $2.475 billion for belimumab, underscoring the commercial potential of the targeted reference products.